TNF gene study in immune TTP patients
Treatments studied
Part of Blood & lymphatic clinical trials.
This study looks at a specific gene (TNFAIP3) in people who have had immune-mediated thrombotic thrombocytopenic purpura (iTTP). It aims to understand how this gene might be linked to the condition. Participants will provide a blood or DNA sample for genetic testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with immune-mediated TTP (iTTP).
- You are 12 years old or older.
- You are Caucasian and of Italian origin.
- You are willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) during an acute episode. It aims to better understand and improve care for this rare blood disorder.
This study looks back at medical records of people with immune-mediated thrombotic thrombocytopenic purpura (TTP), a rare blood clotting disorder. It aims to better understand the disease and how it is treated.
This trial is looking at the immune system's role in thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. It may help researchers understand the condition better and possibly improve future treatments.
This study looks at a gene (CTLA-4) that may affect how the immune system works in children with a new diagnosis of ITP. By understanding this gene, researchers hope to learn more about ITP and improve future care.
This is a real-world registry that collects information about people diagnosed with thrombotic thrombocytopenic purpura (TTP) in Spain and Portugal. It helps researchers understand TTP patterns and outcomes, and participation is voluntary.
This study is a national registry that collects medical information from people diagnosed with a type of blood-clotting disorder called acquired TTP (aTTP). It may help researchers better understand the disease and how it’s managed, without necessarily changing your treatment.
Hear when a new Thrombotic Thrombocytopenic Purpura, Acquired trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.